Dreyer NA[au] - Search Results

Year	Number of Results
1978	1
1980	1
1981	2
1982	3
1983	1
1986	2
1988	2
1990	2
1991	1
1993	4
1994	1
1995	3
1996	5
1997	4
1999	4
2001	1
2002	1
2003	1
2009	1
2010	3
2011	5
2012	3
2013	2
2014	4
2015	3
2016	4
2017	2
2018	3
2019	5
2020	9
2021	7
2022	5

1

Trial designs using real-world data: The changing landscape of the regulatory approval process.

Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Baumfeld Andre E, et al. Among authors: dreyer na. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1201-1212. doi: 10.1002/pds.4932. Epub 2019 Dec 10. Pharmacoepidemiol Drug Saf. 2020. PMID: 31823482 Free PMC article. Review.

2

Bridging the Gap Between RCTs and RWE Through Endpoint Selection.

LoCasale RJ, Pashos CL, Gutierrez B, Dreyer NA, Collins T, Calleja A, Seewald MJ, Plumb JM, Liwing J, Tepie MF, Khosla S. LoCasale RJ, et al. Among authors: dreyer na. Ther Innov Regul Sci. 2021 Jan;55(1):90-96. doi: 10.1007/s43441-020-00193-5. Epub 2020 Jul 6. Ther Innov Regul Sci. 2021. PMID: 32632753 Free PMC article.

3

Real-world evidence to support regulatory decision making: New or expanded medical product indications.

Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA. Franklin JM, et al. Among authors: dreyer na. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):685-693. doi: 10.1002/pds.5222. Epub 2021 Mar 18. Pharmacoepidemiol Drug Saf. 2021. PMID: 33675248 Review.

4

Modernizing Regulatory Evidence with Trials and Real-World Studies.

Dreyer NA, Hall M, Christian JB. Dreyer NA, et al. Ther Innov Regul Sci. 2020 Sep;54(5):1112-1115. doi: 10.1007/s43441-020-00131-5. Epub 2020 Feb 18. Ther Innov Regul Sci. 2020. PMID: 32067187 Free PMC article. No abstract available.

5

Masking in Pragmatic Trials: Who, What, and When to Blind.

Christian JB, Brouwer ES, Girman CJ, Bennett D, Davis KJ, Dreyer NA. Christian JB, et al. Among authors: dreyer na. Ther Innov Regul Sci. 2020 Mar;54(2):431-436. doi: 10.1007/s43441-019-00073-7. Epub 2020 Jan 8. Ther Innov Regul Sci. 2020. PMID: 32072597

6

Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint Selection.

LoCasale RJ, Pashos CL, Gutierrez B, Dreyer NA, Collins T, Calleja A, Seewald MJ, Plumb JM, Liwing J, Tepie MF, Khosla S. LoCasale RJ, et al. Among authors: dreyer na. Ther Innov Regul Sci. 2021 Jan;55(1):97. doi: 10.1007/s43441-020-00225-0. Ther Innov Regul Sci. 2021. PMID: 33128171 Free PMC article. No abstract available.

7

The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness.

Cocoros NM, Arlett P, Dreyer NA, Ishiguro C, Iyasu S, Sturkenboom M, Zhou W, Toh S. Cocoros NM, et al. Among authors: dreyer na. Clin Pharmacol Ther. 2021 May;109(5):1189-1196. doi: 10.1002/cpt.2045. Epub 2020 Oct 8. Clin Pharmacol Ther. 2021. PMID: 32911562

8

Making observational studies count: shaping the future of comparative effectiveness research.

Dreyer NA. Dreyer NA. Epidemiology. 2011 May;22(3):295-7. doi: 10.1097/EDE.0b013e3182126569. Epidemiology. 2011. PMID: 21464648 Review. No abstract available.

9

Considerations when evaluating real-world data quality in the context of fitness for purpose.

Reynolds MW, Bourke A, Dreyer NA. Reynolds MW, et al. Among authors: dreyer na. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1316-1318. doi: 10.1002/pds.5010. Epub 2020 May 6. Pharmacoepidemiol Drug Saf. 2020. PMID: 32374042 Free PMC article. No abstract available.

10

Registries for robust evidence.

Dreyer NA, Garner S. Dreyer NA, et al. JAMA. 2009 Aug 19;302(7):790-1. doi: 10.1001/jama.2009.1092. JAMA. 2009. PMID: 19690313 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results